Varespladib: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   Serious outcomes   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 18 patientsc19early.org

Varespladib for COVID-19

Serious outcome risk
Varespladib
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−120%
Mortality (1)−120%
Ventilation (1)−240%
RCTs (1)−120%
Late (1)−120%
00.511.5+
← Varespladib
reduces riskIncreased
risk →
c19early.org
October 2026

Varespladib COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Lickteig (DB RCT)−120%2.20 · 0.11–44.51death1/150/3STAIRS
Late treatment−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.62
All studies−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6200.511.52+
Rotate screen for more detailsIncrease width for more details
← Varespladib
reduces riskVarespladib
increases risk →
c19early.org
October 2026

Varespladib COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Lickteig (DB RCT)−120%2.20 · 0.11–44.511/150/3STAIRS
Late treatment−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.62
All studies−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6200.511.52+
Rotate screen for more detailsIncrease width for more details
← Varespladib
reduces riskVarespladib
increases risk →
c19early.org
October 2026

Varespladib COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Lickteig (DB RCT)−240%3.40 · 0.20–57.722/150/3STAIRS
Late treatment−240%3.40 · 0.20–57.722/150/3240% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4
All studies−240%3.40 · 0.20–57.722/150/3240% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.400.511.52+
Rotate screen for more detailsIncrease width for more details
← Varespladib
reduces riskVarespladib
increases risk →
c19early.org
October 2026

Varespladib COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Lickteig (DB RCT)−120%2.20 · 0.11–44.51death1/150/3STAIRS
Late treatment−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.62
All studies−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6200.511.52+
Rotate screen for more detailsIncrease width for more details
← Varespladib
reduces riskVarespladib
increases risk →
c19early.org
October 2026

Varespladib COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Lickteig (DB RCT)−120%2.20 · 0.11–44.51death1/150/3STAIRS
Late treatment−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.62
All studies−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6200.511.52+
Rotate screen for more detailsIncrease width for more details
← Varespladib
reduces riskVarespladib
increases risk →
c19early.org
October 2026

Varespladib COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Lickteig (DB RCT)−120%2.20 · 0.11–44.511/150/3STAIRS
Late treatment−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.62
All studies−120%2.20 · 0.11–44.511/150/3120% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.6200.511.52+
Rotate screen for more detailsIncrease width for more details
← Varespladib
reduces riskVarespladib
increases risk →